Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Significant Decline in Short Interest

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 723,800 shares, a drop of 31.1% from the April 15th total of 1,050,000 shares. Based on an average daily volume of 524,900 shares, the days-to-cover ratio is presently 1.4 days.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. PEAK6 Investments LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA by 640.9% in the 1st quarter. PEAK6 Investments LLC now owns 15,686 shares of the company’s stock worth $528,000 after acquiring an additional 18,586 shares during the period. Northern Trust Corp raised its holdings in Fresenius Medical Care AG & Co. KGaA by 9.5% in the 1st quarter. Northern Trust Corp now owns 166,470 shares of the company’s stock worth $5,607,000 after acquiring an additional 14,445 shares during the period. Interchange Capital Partners LLC bought a new position in Fresenius Medical Care AG & Co. KGaA in the 1st quarter worth $229,000. Clearbridge Investments LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA by 29.0% in the 1st quarter. Clearbridge Investments LLC now owns 229,672 shares of the company’s stock worth $7,735,000 after acquiring an additional 51,585 shares during the period. Finally, Freestone Capital Holdings LLC bought a new position in Fresenius Medical Care AG & Co. KGaA in the 1st quarter worth $390,000. Hedge funds and other institutional investors own 4.73% of the company’s stock.

FMS has been the topic of a number of research analyst reports. Jefferies Financial Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to an “underperform” rating and lowered their price objective for the company from $32.40 to $30.30 in a research note on Friday, February 11th. Societe Generale lowered their price objective on shares of Fresenius Medical Care AG & Co. KGaA from €61.00 ($64.21) to €57.00 ($60.00) in a research note on Friday, February 25th. Credit Suisse Group lowered their price objective on shares of Fresenius Medical Care AG & Co. KGaA from €66.00 ($69.47) to €61.00 ($64.21) in a research note on Tuesday, March 1st. JPMorgan Chase & Co. raised their price objective on shares of Fresenius Medical Care AG & Co. KGaA from €48.70 ($51.26) to €51.00 ($53.68) and gave the company an “underweight” rating in a research note on Thursday, May 5th. Finally, StockNews.com assumed coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, May 10th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $51.63.

Shares of NYSE:FMS traded up $0.41 during trading on Friday, reaching $29.21. 486,000 shares of the company traded hands, compared to its average volume of 409,242. The firm has a fifty day simple moving average of $32.46 and a 200 day simple moving average of $32.47. The firm has a market cap of $17.12 billion, a P/E ratio of 16.69, a price-to-earnings-growth ratio of 1.18 and a beta of 1.17. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $28.75 and a 1-year high of $42.45. The company has a quick ratio of 0.93, a current ratio of 1.26 and a debt-to-equity ratio of 0.51.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) last issued its earnings results on Wednesday, May 4th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.08. The company had revenue of $5.10 billion during the quarter, compared to analyst estimates of $4.97 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.91% and a return on equity of 6.99%. As a group, research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.99 EPS for the current year.

The firm also recently declared an annual dividend, which will be paid on Friday, May 27th. Stockholders of record on Monday, May 16th will be issued a dividend of $0.7093 per share. The ex-dividend date is Friday, May 13th. This represents a dividend yield of 3.4%. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio is currently 32.57%.

About Fresenius Medical Care AG & Co. KGaA (Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Stories

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.